$1.54 Billion is the total value of Nantahala Capital Management's 118 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 125.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IWM | Buy | ISHARES TRput | $296,412,000 | +58.4% | 1,700,000 | +49.8% | 19.21% | +58.6% |
| IWM | Buy | ISHARES TRrussell 2000 etf | $120,496,011 | +869.4% | 691,076 | +816.9% | 7.81% | +871.4% |
| IMAX | Buy | IMAX CORP | $41,002,393 | +7.4% | 2,796,889 | +3.5% | 2.66% | +7.6% |
| APEN | Buy | APOLLO ENDOSURGERY INC | $40,444,571 | +84.7% | 4,056,627 | +2.1% | 2.62% | +85.0% |
| LXFR | Buy | LUXFER HLDGS PLC | $33,645,817 | -0.7% | 2,452,319 | +4.9% | 2.18% | -0.5% |
| QURE | Buy | UNIQURE NVcall | $26,925,159 | +43.5% | 1,187,700 | +18.8% | 1.74% | +43.7% |
| IMTX | Buy | IMMATICS N.V | $23,939,670 | -11.8% | 2,748,527 | +1.3% | 1.55% | -11.6% |
| PTON | Buy | PELOTON INTERACTIVE INC | $19,017,761 | +18.5% | 2,395,184 | +3.4% | 1.23% | +18.7% |
| HGV | New | HILTON GRAND VACATIONS INC | $15,924,728 | – | 413,200 | +100.0% | 1.03% | – |
| AUTL | Buy | AUTOLUS THERAPEUTICS PLCspon ads | $14,785,834 | +32.5% | 7,782,018 | +49.2% | 0.96% | +32.7% |
| Buy | DARIOHEALTH CORP | $10,557,720 | +3.9% | 2,466,757 | +12.4% | 0.68% | +4.0% | |
| RMBL | Buy | RUMBLEON INC | $9,636,360 | +140.3% | 1,489,391 | +528.5% | 0.62% | +140.4% |
| Buy | AURA BIOSCIENCES INC | $8,386,886 | +20.6% | 798,751 | +108.1% | 0.54% | +20.9% | |
| BVS | Buy | BIOVENTUS INC | $8,269,978 | +211.8% | 3,168,574 | +736.4% | 0.54% | +211.6% |
| PAYO | Buy | PAYONEER GLOBAL INC | $7,663,314 | +228.8% | 1,084,831 | +181.5% | 0.50% | +229.1% |
| TSHA | Buy | TAYSHA GENE THERAPIES INC | $6,779,469 | +108.9% | 2,999,765 | +86.2% | 0.44% | +109.0% |
| ZM | New | ZOOM VIDEO COMMUNICATIONS INcall | $6,774,000 | – | 100,000 | +100.0% | 0.44% | – |
| ESTA | New | ESTABLISHMENT LABS HLDGS INCcall | $6,565,000 | – | 100,000 | +100.0% | 0.42% | – |
| Buy | VENTYX BIOSCIENCES INC | $5,181,902 | +27.3% | 158,033 | +35.5% | 0.34% | +27.3% | |
| New | ABEONA THERAPEUTICS INC | $4,187,835 | – | 272,731 | +100.0% | 0.27% | – | |
| PNT | Buy | POINT BIOPHARMA GLOBAL INC | $4,171,272 | +172.8% | 572,191 | +189.3% | 0.27% | +172.7% |
| New | WEBER INCcl a | $4,025,000 | – | 500,000 | +100.0% | 0.26% | – | |
| FULC | New | FULCRUM THERAPEUTICS INC | $3,640,000 | – | 500,000 | +100.0% | 0.24% | – |
| AAN | Buy | THE AARONS COMPANY INC | $3,448,435 | +76.1% | 288,572 | +43.2% | 0.22% | +76.4% |
| MED | New | MEDIFAST INC | $3,460,500 | – | 30,000 | +100.0% | 0.22% | – |
| MDXG | New | MIMEDX GROUP INC | $3,190,117 | – | 1,147,524 | +100.0% | 0.21% | – |
| ACER | Buy | ACER THERAPEUTICS INC | $3,077,739 | +217.9% | 1,226,191 | +76.0% | 0.20% | +215.9% |
| New | DISC MEDICINE INC | $3,063,181 | – | 162,762 | +100.0% | 0.20% | – | |
| DHC | New | DIVERSIFIED HEALTHCARE TR | $2,726,262 | – | 4,215,000 | +100.0% | 0.18% | – |
| OPTN | New | OPTINOSE INC | $2,682,500 | – | 1,450,000 | +100.0% | 0.17% | – |
| AGLE | Buy | AEGLEA BIOTHERAPEUTICS INC | $2,074,625 | +6.3% | 4,611,302 | +24.3% | 0.13% | +6.3% |
| ENVA | New | ENOVA INTL INC | $2,043,202 | – | 53,250 | +100.0% | 0.13% | – |
| BMTX | New | BM TECHNOLOGIES INC | $1,603,513 | – | 307,776 | +100.0% | 0.10% | – |
| New | AKUMIN INC | $1,586,363 | – | 2,206,960 | +100.0% | 0.10% | – | |
| WNC | New | WABASH NATL CORPput | $1,507,420 | – | 66,700 | +100.0% | 0.10% | – |
| CRMT | New | AMERICAS CAR-MART INC | $1,083,900 | – | 15,000 | +100.0% | 0.07% | – |
| DS | New | DRIVE SHACK INC | $1,072,825 | – | 6,500,000 | +100.0% | 0.07% | – |
| ADCT | New | ADC THERAPEUTICS SA | $934,234 | – | 243,290 | +100.0% | 0.06% | – |
| DAKT | New | DAKTRONICS INC | $823,967 | – | 292,187 | +100.0% | 0.05% | – |
| CVNA | New | CARVANA COcall | $711,000 | – | 150,000 | +100.0% | 0.05% | – |
| AVTE | New | AEROVATE THERAPEUTICS INC | $460,010 | – | 15,700 | +100.0% | 0.03% | – |
| New | JOURNEY MED CORP | $433,912 | – | 225,996 | +100.0% | 0.03% | – | |
| CYTK | New | CYTOKINETICS INC | $220,028 | – | 4,802 | +100.0% | 0.01% | – |
| SGU | New | STAR GROUP L Punit ltd partnr | $152,806 | – | 12,681 | +100.0% | 0.01% | – |
| New | KINTARA THERAPEUTICS INC | $81,998 | – | 11,901 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
About Nantahala Capital Management
Nantahala Capital Management is a hedge fund that was founded in 2004 by Wil Harkey. The firm is headquartered in Connecticut and has additional offices in New York and North Carolina. Nantahala Capital Management primarily invests in the technology, healthcare, and consumer sectors. The firm has a long-term investment approach and seeks to identify undervalued companies with strong growth potential.
Wil Harkey serves as the CEO and Chief Investment Officer of Nantahala Capital Management. He has over 20 years of experience in the finance industry and previously worked at Goldman Sachs and Maverick Capital. In addition to Harkey, the firm's leadership team includes COO and General Counsel, David Kozak, and CFO, Michael Kozak.
Nantahala Capital Management has a strong track record of generating positive returns for its investors. The firm's flagship fund, the Nantahala Fund, has delivered an annualized return of over 20% since its inception in 2006. The firm's success can be attributed to its disciplined investment approach and focus on long-term value creation.
Overall, Nantahala Capital Management is a well-respected hedge fund with a talented leadership team and a strong track record of performance. However, as with any investment, it is important for investors to conduct their own due diligence and carefully consider the risks before investing in the firm's funds.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ISHARES TR | 42 | Q3 2023 | 27.2% |
| CODEXIS INC | 42 | Q3 2023 | 3.9% |
| PATHWARD FINANCIAL INC | 35 | Q3 2023 | 6.3% |
| SCIENTIFIC GAMES CORP | 34 | Q3 2022 | 5.3% |
| DOVER MOTORSPORTS INC | 34 | Q3 2021 | 0.5% |
| GOLDEN ENTMT INC | 33 | Q3 2023 | 2.1% |
| QAD INC | 32 | Q3 2021 | 2.6% |
| SCIENTIFIC GAMES CORP | 31 | Q4 2021 | 7.7% |
| DOLBY LABORATORIES INC | 31 | Q4 2020 | 5.6% |
| LINCOLN EDL SVCS CORP | 31 | Q4 2021 | 0.7% |
View Nantahala Capital Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AYTU BIOPHARMA, INC | June 16, 2023 | 1,086,812 | 19.7% |
| Acer Therapeutics Inc. | February 14, 2023 | 1,226,191 | 7.5% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 4,611,302 | 7.5% |
| AKUMIN INC. | February 14, 2023 | 2,206,960 | 2.5% |
| ALTA EQUIPMENT GROUP INC. | February 14, 2023 | 1,188,985 | 3.7% |
| Apollo Endosurgery, Inc. | February 14, 2023 | 4,056,627 | 9.9% |
| Autolus Therapeutics plc | February 14, 2023 | 7,782,018 | 4.7% |
| Bioventus Inc. | February 14, 2023 | 3,168,574 | 5.1% |
| CATALYST BIOSCIENCES, INC. | February 14, 2023 | 438,055 | 1.4% |
| Drive Shack Inc. | February 14, 2023 | 6,500,000 | 7.0% |
View Nantahala Capital Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-21 |
| 4 | 2024-03-15 |
| SC 13G | 2024-03-11 |
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Nantahala Capital Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.